Dose-Escalated Radiation Therapy for Muscle-Invasive Bladder Cancer: A Retrospective Analysis
Li Chan, Anzela Anzela, Viet Do, Karen Wong, Felicia Roncolato, Joseph Descallar, Matthew Stanowski, Paul Sved, Mark Sidhom · 2026
Read Dose-Escalated Radiation Therapy for Muscle-Invasive Bladder Cancer: A Retrospective Analysis by Li Chan, Anzela Anzela, Viet Do, Karen Wong, Felicia Roncolato, Joseph Descallar, Matthew Stanowski, Paul Sved, Mark Sidhom (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13571918.txt.
Description
Li Chan and colleagues compare, in a 2026 multicenter retrospective analysis, higher versus standard radiation doses inside bladder-preserving treatment for muscle-invasive bladder cancer. Return of cancer inside the bladder remains a risk in this approach. One hundred seven patients treated between 2015 and 2025 were followed for a median of twenty-three months.
Boosted dosing, delivered as a focused extra dose during the same sessions, clearly improved two-year control of invasive disease inside the bladder after accounting for tumor stage. Control of noninvasive disease, spread-free survival, overall survival, and bladder preservation did not differ, and side effects on urinary and bowel organs were similar. The gain is narrow but real: fewer invasive returns at no extra toxicity cost.
Catalog record
| CREATOR | Li Chan, Anzela Anzela, Viet Do, Karen Wong, Felicia Roncolato, Joseph Descallar, Matthew Stanowski, Paul Sved, Mark Sidhom |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |